CRISPR THERAPEUTICS AG (CRSP) Return on equity 2016–2025
CRISPR THERAPEUTICS AG (CRSP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-30.3%FY2025 · since FY2016: -10.0% → -30.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -30.3% | -11.3 pp |
| FY2024 | -19.0% | -10.8 pp |
| FY2023 | -8.2% | +26.5 pp |
| FY2022 | -34.7% | -50.4 pp |
| FY2021 | 15.7% | +36.7 pp |
| FY2020 | -21.0% | -28.1 pp |
| FY2019 | 7.1% | +49.2 pp |
| FY2018 | -42.1% | -5.7 pp |
| FY2017 | -36.4% | -26.4 pp |
| FY2016 | -10.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice